Global
Cardiovascular Disease Drugs Market to 2023-Expiries, Acquisitions and New
Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and
Dyslipidemia to Shake-Up the Competitive Landscape
The Cardiovascular
Disease (CVD) therapy area encompasses a range of different diseases
and conditions affecting the heart and/or blood vessels. The most crucial risk
factors for CVD are hypertension and dyslipidemia, which accelerate the
development of atherosclerotic plaque buildup within blood vessels. As atheroma
develops it causes the affected blood vessels to narrow, restricting blood flow
to the body, brain or heart, depending on its locale. It is also possible for
the fibrous cap of this plaque to break off, triggering the coagulation cascade
and causing a thrombus to form locally, which can completely occlude blood
flow.
The treatments of
CVD typically focus on prevention by controlling risk factors. As such, the
treatments usually fall within three categories: Anti-hypertensives, which aim
to maintain blood pressure within a normal range; anti-dyslipidemic drugs,
which aim to modify lipid levels to a normal range; and anti-thrombotic drugs,
which aim to prevent thrombi formation by inhibiting the coagulation cascade or
platelet aggregation.
There has been vast
scientific innovation in the CVD therapeutics market in recent decades,
particularly within the anti-dyslipidemia market. This was seen first with the
introduction of statins such as Lipitor (atorvastatin), and more recently with
the introduction of protein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors. However, other areas such as the heart failure market remain poorly
treated. Dyslipidemia and hypertension have continuing high levels of
development within the current pipeline and, despite high levels of generic
development, there is also a large degree of innovation, with targets such as
apolipoproteins and elements of the reverse lipid transport pathway. In
addition, the current pipeline includes nearly 200 products for the treatment
of heart failure, suggesting an increase in interest in treating the disease.
With over 1,400
products in active development, the pipeline for CVD is extensive. Does current
pipeline innovation hold the potential to change the CVD market in the near
future? The clinical trials process for CVD drugs is complex. What is the risk
of a CVD drug failing to reach the market? What is the risk of a drug failing
at a specific Phase? The CVD market landscape is forecast to undergo a period
of substantial change following key approvals, patent expiries and
acquisitions. Which of the leading companies will have the highest market share
by 2023? What strategies have these companies adopted to achieve market growth?
There has been a moderately high level of deal activity in recent years. How do
deal frequency and value compare between target families and molecule types?
Key topics covered in the report:
Global
Cardiovascular Disease Drugs Market
Global
Cardiovascular Disease Drugs Market Outlook
Global
Cardiovascular Disease Drugs Market Value
Global
Cardiovascular Disease Drugs Market Competition Analysis
Global
Cardiovascular Disease Drugs Industry Growth Analysis
Global
Cardiovascular Disease Drugs Market Size
Global
Cardiovascular Disease Treatment
Heart Disease
Treatment in Global
Global
Cardiovascular Disease Drugs Market Forecast
Global
Cardiovascular Disease Drugs Market Revenue
Global
Cardiovascular Disease Drugs Market Share
Global
Cardiovascular Disease Drugs Market SWOT Analysis
Global
Cardiovascular Disease Drugs Market Demand
Global Heart
Disease Medical Treatment
To know more, click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head
Marketing & Communications
+91-9015378249
